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Abstract Candidosis has been attributed to C. albicans;
however, infections caused by non-Candida albicans Can-
dida (NCAC) species are increasingly being recognised. The
ability of Candida to grow as a biofilm is an important feature
that promotes both infection and persistence in the host. The
biofilms’ activity is significant since high activity might be
associated with enhanced expression of putative virulence
factors, whilst in contrast low activity has previously been
suggested as a mechanism for resistance of biofilm cells to
antimicrobials. The aim of this study was to determine the
metabolic activity of in vitro biofilms formed by different
clinical isolates of NCAC species. The in situ total metabolic
activity of C. parapsilosis, C. tropicalis and C. glabrata
biofilms was determined using 2,3-(2-methoxy-4-nitro-5-
sulphophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium
hydroxide (XTT) reduction assay, and the number of culti-
vable cells was also established by CFU (colony forming
unit) counts. The biofilm structure was assessed by scanning
electron microscopy (SEM). Results showed that total bio-
film metabolic activity was species and strain dependent.
C. glabrata exhibited the lowest biofilm metabolic activity
despite having the highest number of biofilm cultivable cells.
Similarly, the metabolic activity of resuspended C. glabrata
biofilm and planktonic cells was lower than that of the other
species. This study demonstrates the existence of intrinsic
activity differences amongst NCAC species, which could
have important implications in terms of species relative
virulence. Furthermore, the absence of an obvious correla-
tion, between cultivable cells number and total biofilm
activity, raises the question about which parameter is the
most appropriate for the in vitro assessment of biofilms and
their potential clinical significance.
Introduction
Candidosis is the most prevalent opportunistic fungal
infection of humans and of particular significance into
patients undergoing treatment for cancer [17], organ
transplantation [10] and receiving broad-spectrum antibi-
otics [26]. Candidosis is also one of the most common and
persistent infections in HIV-infected individuals and AIDS
patients [27].
Amongst Candida species, Candida albicans is the most
commonly isolated and responsible for the majority of
superficial and systemic infections [23]. However, many
non-Candida albicans Candida (NCAC) species, such as
Candida glabrata, Candida parapsilosis and Candida
tropicalis have recently emerged as important pathogens in
suitably debilitated individuals. This fact is highlighted by
recent epidemiology studies reporting that NCAC are
currently estimated to be responsible for approximately
60% of fungemia [4, 6].
A major virulence factor of Candida is its ability to adapt
to a variety of different habitats and the consequent for-
mation of surface-attached microbial communities known
as biofilms [7, 8]. Candida biofilms can develop on natural
host surfaces or on biomaterials used in indwelling medical
devices. Importantly, such biofilms are phenotypically
distinct from their ‘free-living’ or planktonic forms, with
biofilms exhibiting elevated resistance to host defences and
administered antimicrobial agents [3, 11, 27]. The clinical
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significance of biofilms is highlighted by recent estimates
that over 65% of all hospital infections originate from these
microbial communities [21]. As a consequence researchers
are now recognising the importance of studying biofilm
communities rather than planktonic forms when character-
ising the pathogenic potential of microorganisms. So far, a
variety of methods have been described for both the in vitro
production of biofilms and their subsequent characterisa-
tion. Indirect methods based on 96-well microtiter plate
assays, which allow the simultaneous quantification of
yeasts in a large number of biofilm samples, have been
recommended due to their simplicity and sensitivity [13,
18]. A frequently used approach to quantify biofilm cells
activity has been the reduction assay of the tetrazolium salt
2,3-(2-methoxy-4-nitro-5-sulphophenyl)-5-[(phenylamino)
carbonyl]-2H-tetrazolium hydroxide (XTT). In this colori-
metric method, XTT is reduced to an XTT formazan product
by mitochondrial dehydrogenases of metabolically active
cells. The resulting colorimetric changes are considered to
be proportional to the number of living cells and their
metabolic activity [13, 18].
Previous Candida biofilm studies have been mainly
focussed on C. albicans biofilms [2, 5, 13, 15, 16], with
very few examining NCAC species [1, 12, 28]. Further-
more, the vast majority of candidal biofilm research has
been focussed on the assessment of biofilm development
either by biomass determination or by quantifying the
number of cells in the biofilm. The activity of the biofilm
itself or its cellular composition has rarely been investi-
gated [18]. This oversight is important given the fact that
biofilm activity has significance in terms of pathogenicity
as it is a likely indicator of growth, production of hydro-
lytic enzymes and, in the case of reduced activity, of
possible resistance to antimicrobial activity. Therefore,
considering that the biofilm activity is a requirement in
Candida infections, the aim of this study was to determine
the metabolic activity of in vitro biofilms formed by dif-
ferent clinical isolates of NCAC species.
Materials and Methods
Organisms and Growth Conditions
A total of 18 clinical strains (Table 1) of C. parapsilosis
(n = 6), C. tropicalis (n = 6) and C. glabrata (n = 6) that
had previously been recovered from oral, vaginal or urinary
tract infections were used in this study. Strains isolated
from vaginal and urinary tract infections were kindly pro-
vided by the Hospital of Sa˜o Marcos (Braga, Portugal).
Candida tropicalis strains 12 and 75 (recovered from the
vaginal tract) were provided by the University of Maringa´
(Maringa´, Brazil). Oral isolates were originally isolated
from patients attending the Clı´nica dos Congregados
(Braga, Portugal). Three reference strains, namely C. par-
apsilosis (ATCC 22019), C. tropicalis (ATCC 750) and
C. glabrata (ATCC 2001) were also included in this study.
The identity of all isolates was confirmed using CHRO-
MagarCandida (CHROMagar, Paris, France) and by PCR
sequencing using specific primers (ITS1 and ITS4) tar-
geting the 5.8S ribosomal RNA subunit gene [29].
Before the experiments, all isolates were cultured on
Sabouraud Dextrose Agar (SDA; Merck, Germany) for
48 h at 37C. Cells were then subcultured in Sabouraud
Dextrose Broth (SDB; Merck, Germany) for 18 h at 37C
in an orbital shaker (120 rev/min). Cells were then har-
vested by centrifugation at 30009g for 10 min at 4C and
washed twice in phosphate buffer saline (PBS pH 7,
0.1 M). The cell pellets were finally resuspended in SDB,
and the cell concentration was adjusted using an improved
Neubauer haemocytometer to a standardised level (1 9 107
or 1 9 108 cells/ml) depending on the experiment.
Biofilm Formation
Biofilms were produced in 96-well microtiter plates
(Orange Scientific, Braine-l’ Alleud, Belgium). Briefly,
standardised inocula (200 ll of yeast cell suspension con-
taining 1 9 107 cells/ml in SDB) were placed into selected
wells and incubated at 37C in an orbital shaker incubator
at 120 rev/min. After 24 h, an aliquot of 100 ll of SDB
medium was removed and an equal volume of fresh SDB
added. The microtiter plates were then incubated for fur-
ther 48 h. Experiments were performed in triplicate and on
at least three separate occasions.
Biofilm Characterisation
In Situ Biofilm Metabolic Activity
An XTT reduction assay [13, 14] was used to determine the
in situ biofilm metabolic activity of the NCAC strains.
After biofilm formation, the culture medium was aspirated
and the non-adherent cells were removed by washing the
biofilms twice in PBS. A 200 ll aliquot of a solution
containing 100 lg/ll of XTT (2,3-(2-methoxy-4-nitro-5-
sulphophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium
hydroxide) (Sigma–Aldrich, USA) and 10 lg/ll of phen-
azine methosulphate (PMS) (Sigma–Aldrich, USA) was
then added to each pre-washed biofilm and also to the
control wells (to measure background XTT levels). The
plates were then incubated for 3 h in the dark, at 37C with
agitation (120 rev/min). Colorimetric changes were mea-
sured at 490 nm using a microtiter plate reader (Bio-Tek
Synergy HT, Izasa, Portugal) and the absorbance values
were standardised per unit area of well (absorbance/cm2).
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Quantification of Biofilm Cultivable Cells
The number of cultivable biofilm cells was determined by
counting colony forming units (CFUs) following biofilm
cells resuspension. Briefly, biofilms were first washed twice
in PBS to remove loosely attached cells and the biofilm was
then resuspended by repeated pipetting. Complete removal
of the biofilm was confirmed by subsequent crystal violet
staining and spectrophotometric reading for inspection of the
wells. The resuspended biofilm (500 ll) was vigorously
vortexed for 5 min to disrupt the biofilm matrix and serial
decimal dilutions (in PBS) were plated onto SDA. Agar
plates were incubated for 24 h at 37C, and the total CFUs
per unit area (Log CFU/cm2) of microtiter plate well were
enumerated. Experiments were repeated on three occasions
with individual samples evaluated in triplicate.
Biofilm Structure
Biofilm structure was examined by Scanning Electron
Microscopy (SEM). Biofilms were formed by seeding 2 ml
of the standardised cell suspension (1 9 107 cells/ml in
SDB) into 24-well plates (Orange Scientific, Braine-l‘Al-
leud, Belgium) and incubated for 48 h at 37C and 120 rev/
min. After 24 h, 1 ml of SDB medium was removed and an
equal volume of fresh SDB added. At 48 h, the medium
was aspirated and non-adherent cells removed by washing
the biofilms twice with sterile ultra-pure water. Samples
were dehydrated with alcohol (using 70% ethanol for
10 min, 95% ethanol for 10 min and 100% ethanol for
20 min) and air dried for 20 min. Samples were kept in a
desiccator until the base of the wells was removed for
analysis. Prior to observation, the base of the wells was
mounted onto aluminium stubs, sputter-coated with gold
and observed with an S-360 scanning electron microscope
(Leo, Cambridge, USA).
Quantification of Cellular Metabolic Activity
Metabolic Activity of Biofilms Cells
Biofilms were removed from the microtiter plate wells
as described previously and the cell concentration adjusted
to 1 9 108 cells/ml using an improved Neubauer
Table 1 Non-Candida albicans Candida strains used in this study, values of in situ total biofilm activity, relative biofilm activity and metabolic
activity of biofilm and planktonic cells
Species Strains Origin In situ total
biofilm activity
(Abs values/cm2)
±SD
Relative
biofilm activity
(Abs values/
108 CFU)
Cellular metabolic activity
(Abs values/108 cells) ±SD
Biofilm cells Planktonic cells
C. parapsilosis 534638 Urinary tract 0.198 ± 0.01 0.518 0.548 ± 0.08 0.621 ± 0.05
553877 0.099 ± 0.04 0.199 0.323 ± 0.04 0.474 ± 0.13
AD Oral tract 0.297 ± 0.07 0.055 0.387 ± 0.06 0.702 ± 0.19
AM2 0.337 ± 0.13 0.116 0.587 ± 0.09 0.407 ± 0.09
491861 Vaginal 0.405 ± 0.02 1.311 0.534 ± 0.11 0.554 ± 0.11
513143 0.537 ± 0.04 1.677 0.496 ± 0.11 0.669 ± 0.11
ATCC 22019 Reference 0.454 ± 0.09 1.134 0.221 ± 0.05 0.492 ± 0.05
C. tropicalis 519468 Urinary tract 0.115 ± 0.03 0.295 0.273 ± 0.01 0.702 ± 0.15
544123 0.179 ± 0.02 1.059 0.283 ± 0.07 0.867 ± 0.07
AG1 Oral tract 0.322 ± 0.05 1.094 0.345 ± 0.07 0.467 ± 0.04
T2.2 0.259 ± 0.02 0.922 0.162 ± 0.02 0.585 ± 0.09
12 Vaginal 0.185 ± 0.01 0.041 0.313 ± 0.02 0.298 ± 0.01
75 0.137 ± 0.03 3.672 0.376 ± 0.07 0.323 ± 0.01
ATCC 750 Reference 0.507 ± 0.09 16.80 0.665 ± 0.11 0.688 ± 0.02
C. glabrata 562123 Urinary tract 0.223 ± 0.04 0.006 0.228 ± 0.07 0.281 ± 0.09
513100 0.129 ± 0.03 0.002 0.100 ± 0.02 0.149 ± 0.01
D1 Oral tract 0.237 ± 0.09 0.006 0.179 ± 0.03 0.138 ± 0.07
AE2 0.201 ± 0.08 0.052 0.167 ± 0.02 0.135 ± 0.04
534784 Vaginal 0.172 ± 0.07 0.049 0.131 ± 0.03 0.079 ± 0.03
585626 0.118 ± 0.05 0.031 0.084 ± 0.02 0.201 ± 0.06
ATCC 2001 Reference 0.238 ± 0.06 0.084 0.181 ± 0.05 0.732 ± 0.14
SD standard deviation
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haemocytometer. Cells from 1 ml of the standardised cell
preparation were harvested by centrifugation (30009g), and
the supernatant was discarded. An aliquot of 1 ml of XTT
solution (100 lg/ll of XTT and 10 lg/ll of PMS) was
added to the yeast cells pellet. The mixture was then incu-
bated in the dark for 3 h at 37C and 120 rev/min. Colori-
metric changes were measured as previously described and
activity expressed as absorbance/1 9 108 cells. Experi-
ments were repeated on three occasions with individual
samples evaluated in triplicate.
Metabolic Activity of Planktonic Cells
Cells were inoculated in SDB for 18 h at 37C under
agitation (120 rev/min) and then harvested by centrifuga-
tion (30009g for 10 min at 4C) and washed twice in PBS.
After resuspension in PBS, the cell concentration was
adjusted to 1 9 108 cells/ml and the cellular metabolic
activity was measured as previously described for the
resuspended biofilm cells.
Statistical Analysis
Results were compared using a one-way analysis of vari-
ance (ANOVA) by applying Levene’s test of homogeneity
of variance and the Tukey multiple-comparisons test, using
SPSS software (SPSS [Statistical Package for the Social
Sciences], Inc., Chicago, IL). All tests were performed with
a confidence level of 95%.
Results and Discussion
The primary aim of this study was to determine the total
in situ biofilm activity of 21 strains of NCAC species using
an XTT reduction assay (Fig. 1). It was clearly evident that
biofilm metabolic activity was species and strain depen-
dent. Specifically, the overall mean metabolic activity of
C. glabrata (Abs/cm2 = 0.19 ± 0.05) biofilms was lower
than for C. parapsilosis (Abs/cm2 = 0.33 ± 0.15) and
C. tropicalis (Abs/cm2 = 0.24 ± 0.14). Such intra species
variation in terms of biofilm formation has previously been
demonstrated albeit using parameters other than activity
[12, 28]. It was interesting to note that in the case of
C. parapsilosis, both urinary tract isolates (534638 and
553877) had significantly (P \ 0.05) lower biofilm meta-
bolic activity (Abs/cm2 = 0.20 ± 0.01; 0.09 ± 0.04)
compared with the other C. parapsilosis strains. Whether
this finding relates to an inherent difference between strains
from distinct pathological origins is unclear, and further
investigation involving larger number of strains from these
conditions is needed to clarify this point.
There are several possible reasons for the observed
species and strain differences in in situ biofilm metabolic
activity. A key factor would obviously be the relative
number of metabolic active cells within the biofilm itself.
In order to analyse this, CFU counts for each biofilm were
determined. In contrast to what would perhaps be expected,
there was no correlation between biofilm metabolic activity
(Fig. 1) and CFU number (Fig. 2). It was evident that
despite C. glabrata biofilms having the lowest metabolic
activity, these biofilms had significantly (P [ 0.05) higher
number of cultivable cells per unit area (Log CFU/
cm2 = 9.16 ± 0.59) when compared with C. tropicalis
(Log CFU/cm2 = 7.34 ± 0.72) and C. parapsilosis (Log
CFU/cm2 = 7.82 ± 0.09). Furthermore, also the intra-
strain variation observed for C. parapsilosis and C. tropi-
calis in terms of biofilm metabolic activity (Fig. 1) was not
associated with differences in CFU numbers (Fig. 2). The
observed discrepancy between in situ total biofilm activity
and the number of cultivable cells does have important
implications for biofilm studies, since it is often assumed
Fig. 1 Absorbance values of
XTT solutions per cm2 of
biofilms formed in SDB for
48 h by different clinical
isolates of C. parapsilosis,
C. tropicalis and C. glabrata.
Error bars represent standard
deviation. * Strains of the same
species that are significantly
different (P \ 0.05)
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that metabolic activity measurements provide a sufficient
correlation to indirectly quantify biofilms [5, 13, 30]. This
situation may be adequate when comparing a single strain
type under different environmental conditions but is
problematic when multiple strains and species are being
compared [19].
In terms of species and strain differences, consideration
has to be given to inherent differences in the relative size,
morphology and biochemistry of cells. It is known that
C. glabrata cells are generally smaller (1–4 lm) than
C. tropicalis (4–8 lm) and C. parapsilosis (2.5–4 lm) [24]
and also have a narrower spectrum of carbohydrate utilisa-
tion [9, 20]. Unlike C. parapsilosis and C. tropicalis,
C. glabrata (Fig. 3) is unable to generate filamentous forms
which may also be expected to exhibit different metabolic
activity, and thus contribute to species differences [18].
Inherent species differences would be supported by the
control experiments (Table 1) where planktonic cultures
illustrated similar differences between the species with
C. glabrata again having lower cellular metabolic activity
compared with the other two species. Specifically, it was
shown that C. glabrata biofilm cells had, on average, a lower
metabolic activity (Abs/1 9 108 cells = 0.15 ± 0.03) than
either C. tropicalis (Abs/1 9 108 cells = 0.35 ± 0.16) or
C. parapsilosis (Abs/1 9 108 cells = 0.45 ± 0.15) cells
(Table 1). There were, however, some discrepancies when
comparing the relative strain hierarchy for metabolic
activity for the planktonic and biofilm cultures. A possible
explanation for this relates to potential additional significant
phenotypic differences occurring between the two lifestyles
[22, 25]. Perhaps the most important of these are those
factors that relate to the promotion, persistence and
virulence of the organisms within the host environment. As
biofilm cells are organised into structured communities
embedded within an extracellular matrix, activity within
biofilms would be dependent on nutrient access and avail-
ability of oxygen, together with removal of waste products.
These factors may vary because of inherent differences in
the biofilms produced by the tested strains and species, with
the resulting alteration in cellular and biofilm metabolic
activity. Indeed, evidences of variation in biofilm spatial
arrangement are possible observed in Fig. 3. For instances
(Fig. 3b), concerning C. tropicalis 12, which possess high
number of CFU (Fig. 2) and low activity (Fig. 1), it is
possible to verify that its biofilm is more cohesive than
C. tropicalis 75, which presents lower CFU number (Fig. 2)
as well as metabolic activity (Fig. 1). The same was
observed for C. glabrata (Fig. 3a) and C. parapsilosis
(Fig. 3c) biofilms. Thus, an effect on the ability of XTT to
diffuse into these ‘different’ biofilms is an aspect that also
cannot be disregarded. When total biofilm activity was
normalised against 1 9 108 CFU of resuspended biofilm
(Table 1), it was evident that the relative biofilm activity of
C. glabrata was 100 times less than C. tropicalis and
10 times lower than C. parapsilosis. Interestingly, this
analysis highlights additional heterogeneity in terms of
relative biofilm metabolic activity between C. parapsilosis
and C. tropicalis. Furthermore, the results indicate that, in
general, biofilms formed by clinical isolates had a much
lower relative activity compared to the corresponding ref-
erence strains, with the exception of C. parapsilosis ATCC
22019.
In summary, this study underlines both species and
strain differences in biofilm metabolic activity which in
Fig. 2 Logarithm of number
cells of C. parapsilosis,
C. tropicalis and C. glabrata per
cm2 of the biofilm formed in
SDB after 48 h. Error bars
represent standard deviation.
* Strains of the same species
that are significantly different
(P \ 0.05)
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part reflects the inherent physiological differences between
the organisms. However, it has also to be considered that
intrinsic biofilm factors may have a direct effect on the
responses obtained. These findings may have significance
concerning the pathogenic potential of the strains tested
when extrapolated to in vivo situations, with the clinical
isolates generally having a lower activity than the equiv-
alent reference species. Such a relatively low activity could
promote persistence of the isolates within a clinical envi-
ronment once the biofilm has become established. Another
important aspect raised by this study is that future research
needs to consider which is the most appropriate parameter
to investigate in vitro biofilm models since total biofilm
activity or cultivable cells number do not necessarily reflect
the behaviour of the biofilm itself.
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